These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 26605922)

  • 21. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
    Menopause; 2010; 17(1):25-54; quiz 55-6. PubMed ID: 20061894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Absolute risk for fracture and WHO guideline. Pharmacological intervention to prevent osteoporotic fractures in the elderly].
    Hosoi T;
    Clin Calcium; 2007 Jul; 17(7):1098-104. PubMed ID: 17607078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are we treating women with postmenopausal osteoporosis for their low BMD or high fracture risk?
    Bone HG; Santora AC; Chattopadhyay A; Liberman U
    J Bone Miner Res; 2005 Nov; 20(11):2064-5. PubMed ID: 16234982
    [No Abstract]   [Full Text] [Related]  

  • 26. Epidemiology, etiology, and diagnosis of osteoporosis.
    Lane NE
    Am J Obstet Gynecol; 2006 Feb; 194(2 Suppl):S3-11. PubMed ID: 16448873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of risk factors for future fracture in patients following distal forearm fracture.
    Mulherin D; Williams S; Smith JA; Edwards J; Sheeran TP; Price T
    Osteoporos Int; 2003 Sep; 14(9):757-60. PubMed ID: 12897979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture.
    Miller RG
    Geriatrics; 2006 Jan; 61(1):24-30. PubMed ID: 16405361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategies for the prevention of senile (type II) osteoporosis: an update.
    Boonen S; Dequeker J
    J Intern Med; 1996 May; 239(5):383-91. PubMed ID: 8642230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical surveillance of osteoporotic patients].
    Passeri G; Passeri M
    Recenti Prog Med; 2003 May; 94(5):211-6. PubMed ID: 12723500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Follow-up treatment for osteoporosis after fracture.
    Hooven F; Gehlbach SH; Pekow P; Bertone E; Benjamin E
    Osteoporos Int; 2005 Mar; 16(3):296-301. PubMed ID: 15221208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture.
    Ferrari S; Reginster JY; Brandi ML; Kanis JA; Devogelaer JP; Kaufman JM; Féron JM; Kurth A; Rizzoli R
    Arch Osteoporos; 2016 Dec; 11(1):37. PubMed ID: 27800591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture.
    Panneman MJ; Lips P; Sen SS; Herings RM
    Osteoporos Int; 2004 Feb; 15(2):120-4. PubMed ID: 14618302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of primary osteoporosis in men.
    Giusti A; Bianchi G
    Clin Interv Aging; 2015; 10():105-15. PubMed ID: 25565793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosis.
    Huang S; Lin H; Zhu X; Chen X; Fan L; Liu C
    Endokrynol Pol; 2014; 65(2):96-104. PubMed ID: 24802732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture.
    Perreault S; Dragomir A; Blais L; Moride Y; Rossignol M; Ste-Marie LG; Fernandès JC
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):248-59. PubMed ID: 18213734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone mineral density thresholds for pharmacological intervention to prevent fractures.
    Siris ES; Chen YT; Abbott TA; Barrett-Connor E; Miller PD; Wehren LE; Berger ML
    Arch Intern Med; 2004 May; 164(10):1108-12. PubMed ID: 15159268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Assessment of risk factors for fractures in postmenopausal women with osteoporosis].
    Ferencz V; Horváth C; Huszár S; Bors K
    Orv Hetil; 2015 Jan; 156(4):146-53. PubMed ID: 25597319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Evaluation of exercise as a preventive therapy for osteoporosis].
    Koike T
    Clin Calcium; 2005 Apr; 15(4):673-7. PubMed ID: 15802783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.